On Monday, Shares of Unilever N.V. (ADR)(NYSE:UN), subtract -0.99% and closed at $42.79 in the last trading session. UN stock opened its last trade at $42.87 and after floating in a range of $4272 to $43.03. The company’s Market capitalization is $127.90 Billion with the total Outstanding Shares of 1.28 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $40.03 and reached to max level of $48.00. Unilever N.V. operates in the fast-moving consumer goods market worldwide. The company operates through Personal Care, Foods, Refreshment, and Home Care segments. The Personal Care segment offers skincare and haircare products, deodorants, and oral care products. This segment markets its products under the Dove, Axe, Lux, Rexona, Sunsilk, Lifebuoy, Vaseline, Signal, Zendium, Dermalogica, Murad, Kate Somerville, and REN brand names. The Foods segment provides soups, bouillons, sauces, snacks, mayonnaise, salad dressings, margarines, and spreads under the Knorr, Hellmanns, Rama, Becel, Maille, Maizena, Fruco, Kissan, Bango, Ladys Choice, and Becel/Flora brands. The Home Care segment provides home care products, such as powders, liquids and capsules, soap bars, and various cleaning products under the brand names of Omo, Surf, Sunlight, Domestos, Comfort, and Pureit brands. The Refreshment segment offers ice cream and tea-based beverages under the Magnum, Heartbrand (Walls), Talenti, Ben & Jerrys, Cornetto, Grom, Lipton, and PG Tips brand names, in addition to operates T2 stores.
Halozyme Therapeutics, Inc. (NASDAQ:HALO), dropped -3.48% and closed at $9.71 in the last trading session. HALO stock opened its last trade at $10.03 and after floating in a range of $9.67 to $10.10. The company’s Market capitalization is $1.20 Billion with the total Outstanding Shares of 129.41 million. During the 52-week trading session the minimum price at which share price traded, registered at $6.96 and reached to max level of $18.65. Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2016 on Mon., Nov. 7, 2016 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2016.